Aprepitant - PlusVitech
Latest Information Update: 16 Apr 2024
At a glance
- Originator PlusVitech
- Class Anti-inflammatories; Antidepressants; Antiemetics; Antineoplastics; Antitussives; Antivirals; Fluorobenzenes; Ketones; Morpholines; Skin disorder therapies; Small molecules; Triazoles
- Mechanism of Action Neurokinin 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Non-small cell lung cancer
Most Recent Events
- 09 Apr 2024 Nanoform and PlusVitech collaborate to develop Aprepitant for Non small cell lung cancer
- 10 Mar 2021 Phase-II clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Turkey (PO) (NCT04840004)